WO2020233598A1 - Attache pour valvule cardiaque, et valvule cardiaque - Google Patents

Attache pour valvule cardiaque, et valvule cardiaque Download PDF

Info

Publication number
WO2020233598A1
WO2020233598A1 PCT/CN2020/091289 CN2020091289W WO2020233598A1 WO 2020233598 A1 WO2020233598 A1 WO 2020233598A1 CN 2020091289 W CN2020091289 W CN 2020091289W WO 2020233598 A1 WO2020233598 A1 WO 2020233598A1
Authority
WO
WIPO (PCT)
Prior art keywords
tether
stent
heart valve
valve
main body
Prior art date
Application number
PCT/CN2020/091289
Other languages
English (en)
Chinese (zh)
Inventor
褚华磊
姚斌
刘香东
Original Assignee
先健科技(深圳)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 先健科技(深圳)有限公司 filed Critical 先健科技(深圳)有限公司
Publication of WO2020233598A1 publication Critical patent/WO2020233598A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body

Definitions

  • the present invention relates to the field of medical equipment, in particular to a tether for heart valves and heart valves.
  • Valve replacement surgery generally can use interventional therapy, which has the advantages of less trauma and low surgical risk, and has a broader market demand.
  • the heart valve 1 includes a skirt stent 11, a valve leaf stent 12, a valve leaflet (not shown in the figure) and a tether 13.
  • the outer diameter of the skirt stent 11 is larger than the opening of the mitral valve MV.
  • the purpose of this application is to provide a tether for a heart valve and a heart valve.
  • a heart valve including:
  • valve stent includes a main body stent and a skirt stent disposed on the main body stent, the skirt stent extending outward along a radial direction of the main body stent;
  • valve leaflets are arranged in the main body stent.
  • the tether is connected with the main body support, and the tether is visible under X-rays.
  • a tether for heart valves including:
  • a core layer made of a polymer material doped with a developing material
  • a braided layer is wrapped around the core layer, and the braided layer is braided by polymer wires.
  • the state of the tether can be observed through DSA during the implantation process. If the tether is twisted or bent under X-rays, the tether can be tightened at this time To make it straight, ensure that the tension between the tether and the valve stent is appropriate, to ensure that the heart valve does not fit poorly under the impact of blood flow, and reduce the probability of paravalvular leakage.
  • the tether by setting the tether to be visible under X-rays, during follow-up, by observing the state of the tether, it can also be judged whether there will be a paravalvular leak.
  • Figure 1 is a schematic diagram of the structure of a heart valve after implantation in the heart in the prior art
  • FIG. 2 is a schematic diagram of the structure of a heart valve according to an embodiment of the application.
  • Fig. 3 is a schematic structural view of the heart valve shown in Fig. 2 from another perspective;
  • FIG. 4 is a schematic diagram of the structure of the heart valve shown in FIG. 2 after being implanted into the heart;
  • Figure 5 is an exploded view of the connector of the heart valve shown in Figure 2;
  • Figure 6 is a schematic structural diagram of the connecting member shown in Figure 5 after being connected to the tether;
  • Fig. 7 is a schematic structural diagram of a tether according to another embodiment of the application.
  • FIG. 8 is a schematic diagram of the structure of the tether shown in FIG. 7 after being knotted
  • Figure 9 is a schematic diagram of the structure of the tether shown in Figure 7 after being knotted;
  • FIG. 10 is a schematic structural diagram of a tether according to another embodiment of the application.
  • FIG. 11 is a schematic diagram of the structure of the tether weaving process shown in FIG. 10;
  • Figure 12 is a test structure diagram of the tether and core layer shown in Figure 10.
  • this application takes the replacement of a mitral valve as an example for description, and the concept of this application can also be used to replace a tricuspid valve, a pulmonary valve, or an aortic valve.
  • the heart valve tissue involved in the present invention refers to one or a combination of several of the body's own heart tissues such as valve annulus, valve leaflets, chordae, papillary muscles.
  • the heart valve In the delivery state, the heart valve is contracted in the delivery system to facilitate delivery; in the unfolded state, the heart valve is separated from the delivery system and is fixed to the heart tissue as a whole.
  • the heart valve 10 includes a valve stent 100, a tether 150, a baffle 170, and a valve leaflet 190.
  • the valve stent 100 includes a main body stent 110, a skirt stent 120 and a fixing part 130, and a skirt stent 120 and a fixing part. 130 are respectively arranged on the main body bracket 110, the skirt bracket 120 and the fixing member 130 are respectively used for fixing the heart tissue in two opposite cavities in the heart, and the tether 150 is connected to the main body bracket 110.
  • the skirt bracket 120 is used to fix the heart tissue on the left atrium side
  • the fixing member 130 is used to fix the heart tissue on the left ventricle side
  • the tether 150 extends from one side of the main body bracket 110 to the outside of the heart. Fixed at the apex of the heart. Specifically, the skirt support 120 extends radially outward from the leaflet support 112, and the skirt support 120 is farther away from the tether 150 than the fixing member 130.
  • the fixing member 130 may also be omitted.
  • the skirt stent 120 of the heart valve 10 can be stuck at the mitral valve annulus to prevent the heart valve 10 from falling into the left ventricle, and the tether 150 can be fixed outside the apex by knotting to prevent the heart valve 10 from moving to the left atrium.
  • the skirt support 120 and the tether 150 can prevent the heart valve 10 from being displaced after implantation.
  • the main body support 110 includes a leaflet support 112, a connecting rod 114, and a connecting piece 116.
  • the skirt support 120 and the fixing piece 130 are disposed on the leaflet support 112.
  • One end of the connecting rod 114 is connected to the leaflet support 112.
  • One end is fixedly connected, the other end is connected to the connecting piece 116, and the tether 150 is connected to the connecting piece 116.
  • the leaflet holder 112 is substantially cylindrical, and has an inflow end and an outflow end opposite to the inflow end.
  • the leaflet support 112 can provide radial support for the heart valve 10 and fix the leaflet 190.
  • the leaflet support 112 includes a wave ring 1121 and a connecting rod 1123.
  • the leaflet support 112 includes a plurality of wave rings 1121 spaced apart along the axial direction of the leaflet support 112.
  • the wave ring 1121 provides the radial support force of the leaflet support 112.
  • the leaflet support 112 includes three wave circles 1121.
  • the three wave rings 1121 are connected and fixed by a plurality of connecting rods 1123.
  • the number of connecting rods 1123 is the same as the number of troughs of the wave ring 1121, and one connecting rod 1123 is fixedly connected to the troughs of the three wave rings 1121 at the same time.
  • the connecting rod 1123 may also be fixedly connected to other positions of the wave ring 1121, such as wave crests.
  • the skirt bracket 120 includes a supporting portion 121 and a raised portion 122.
  • the support portion 121 extends outward from the leaflet support 112 along the radial direction of the leaflet support 112, and the upturned portion 122 is bent and extends from an end of the support portion 121 away from the leaflet support 112 toward the inflow end of the leaflet support 112.
  • the supporting portion 121 is used to fix the heart valve 10 in the human mitral valve annulus of the heart, and the upturned portion 122 is used to prevent the edge of the skirt stent 120 from abrading the left atrial tissue.
  • the distal edge of the radial support portion 121 directly contacts the atrial tissue, which will cause a cutting effect on the atrial tissue under long-term heart beats, causing damage to the atrial tissue.
  • the contact between the skirt stent 120 and the atrial tissue becomes surface contact, which increases the contact area, reduces the contact pressure, and avoids the cutting effect of the skirt stent 120 on the heart tissue and causes Abrasion.
  • the distance between the end of the support portion 121 of the skirt support 120 close to the leaflet support 112 and the inflow end is 1/4 to 1/2 of the axial length of the leaflet support 112.
  • the supporting portion 121 of the skirt bracket 120 is fixedly connected to the wave trough of the wave ring 1121 near the first end of the leaflet bracket 112. In this way, when the heart valve 10 is implanted into the heart, nearly one-third of the axial dimension of the leaflet stent 112 can be located in the left atrium, thereby avoiding excessive implantation of the left ventricle to cause stenosis or even obstruction of the left ventricular outflow tract.
  • the outer contour of the supporting portion 121 of the skirt stent 120 is circular when viewed from the inflow side of the valve blood flow.
  • the outer contour of the supporting portion 121 may also have other shapes, such as D-shaped, D-like, or elliptical.
  • the baffle 170 is used to block the blood flow from overflowing through the valve support 110, and cooperate with the valve leaflet 190 to ensure the unidirectional flow of blood in the heart valve 10.
  • the material of the baffle 170 is PTFE, PET, PU, casing or animal pericardium. Depending on the material, the baffle 170 may be laminated by a hot pressing process or fixed to the valve support 110 by suture. In this embodiment, the baffle 170 covers the surfaces of the leaflet holder 112 and the skirt holder 120. Specifically, the baffle 170 may only cover at least one of the inner surface and the outer surface of the leaflet holder 112.
  • a parylene layer is formed on the non-biological tissue surface of the heart valve 100.
  • a parylene layer is formed on the surface of the baffle 170.
  • the thickness of the parylene layer is 5 nanometers to 5 microns.
  • the material of the parylene layer is C-type parylene.
  • the leaflet 190 is located inside the leaflet support 112 and is fixed to the baffle 170 on the surface of the leaflet support 112.
  • the leaflet 190 is cut from the animal pericardium.
  • the leaflet 190 is roughly fan-shaped, and there are three pieces in total, which are sequentially arranged along the circumferential direction of the leaflet holder 112.
  • the ends of the two adjacent leaflets 190 close to the inner surface of the leaflet holder 112 are joined together to form a valve angle.
  • the peripheral edge of the leaflet 190 is fixed to the leaflet holder 112 and the baffle member 170 by suture, and the valve angle is fixed to the connecting piece.
  • the connecting rod 114 includes a proximal connecting rod 1141, a leaflet support connecting rod 1142, and a joint (not shown).
  • the proximal link 1141 is generally rod-shaped.
  • the leaflet support link 1142 is roughly V-shaped and includes two branch rods extending from one end of the proximal link 1141 to the leaflet support 112. The ends of the two branch rods away from the proximal link 1141 are connected to the leaflet support 112 respectively.
  • each wave trough is connected to a branch rod, so that a plurality of connecting rods 114 are evenly distributed along the outflow end, thereby playing a guiding role when the heart valve 10 is retracted into the sheath.
  • valve leaf support connecting rod 1142 can also have other shapes, for example, it can be in a straight shape, extending directly from one end of the proximal connecting rod 1141 to connect with the trough of the outflow end of the valve leaf support 112, that is, the branch rod The number is the same as that of the proximal link 1141.
  • valve support 100 can also be adjusted as needed.
  • the connecting member 116 includes a socket 1161 and a connecting cover 1163 fixedly connected to the socket 1161.
  • the connecting cover 1163 defines a limiting hole 1162.
  • the end of the connecting rod 114 away from the leaflet holder 112 passes through the limiting hole 1162 and is received in the limiting hole 1162.
  • the connection cover 1163 and the socket 1161 form a cavity.
  • the connecting cover 1163 includes a connecting sleeve 11631 and a spherical cap 11633 formed at one end of the connecting sleeve 11631.
  • the end of the connecting sleeve 11631 away from the spherical cap 11633 is sleeved and fixed with the socket 1161 to form a cavity, and the limiting hole 1162 is an edge connection
  • the sleeve 11631 has a strip hole extending axially.
  • the multiple limiting holes 1162 are evenly distributed along the circumferential direction of the connecting sleeve 11631.
  • the joint 1143 of each connecting rod 114 penetrates through a limiting hole 1162. .
  • the limiting hole 1162 extends from the end of the connecting sleeve 11631 away from the spherical crown 11633 to the middle of the spherical crown 11633, so that when the connecting rod 114 is connected to the connecting cover 1163, the angle of the connecting rod 114 can be reduced in the limiting hole 1162.
  • the angle of deflection, when the heart valve 10 is in a compressed state and an uncompressed state, the connecting rod 114 can adapt to different states of the heart valve 10 by changing the angle.
  • the socket 1161 includes a main body portion 11611 and a socket portion 11613.
  • the main body 11611 is approximately hemispherical and one end is flat.
  • the diameter of the main body 11611 is approximately the same as the diameter of the spherical cap 11633.
  • the plug-in portion 11613 protrudes from the plane of the main body portion 11611 and has a diameter smaller than that of the main body portion 11611.
  • the plug-in portion 11613 is received in the connecting sleeve 11631 and the two are fixed by welding.
  • the socket 1161 is provided with a screw hole 11614, and the screw hole 11614 penetrates the plug portion 11613 and the main body portion 11611.
  • the connecting member 116 further includes a blocking piece 1165.
  • the blocking piece 1165 is received in the connecting sleeve 11631 and is located at an end of the inserting portion 11613 close to the spherical crown 11633.
  • a through hole 11651 corresponding to the screw hole 11614 is opened in the middle of the blocking piece 1165.
  • the blocking piece 1165 can also be omitted.
  • Both ends of the connecting piece 116 are hemispherical, which can reduce the formation of thrombus and reduce the impact on hemodynamics.
  • One end of the tether 150 is inserted into the screw hole 11614 and is received in the cavity formed by the connecting cover 1163 and the socket 1161, and the other end extends out of the connecting piece 116 and passes through the apex of the heart and is knotted and fixed at the apex of the heart.
  • the heart valve 10 is pulled to prevent it from falling off in the left atrium.
  • the tether 150 is visible under X-rays.
  • the heart valve 10 may further include a gasket 180.
  • the material of the gasket 180 is selected from at least one of silica gel, polyester, nylon, ultra-high molecular weight polyethylene, nickel titanium and stainless steel braided wire.
  • the gasket 180 can be a felt-like disc, a disc-like structure woven of titanium nickel wire, or a disc-like structure made of polymer injection molding.
  • the atria begin to contract, and blood in the atria is injected into the ventricles, causing the ventricular pressure to rise.
  • blood enters the aorta from the left ventricle through the aortic valve, and the pressure generated by the contraction of the left ventricle causes the blood to enter the capillaries.
  • the tether 150 exerts a pulling force on the heart valve 10 during ventricular diastole and systole.
  • the tension between the tether 150 and the heart valve 10 is weak, there will be gaps in the fit between the heart valve 10 and the mitral valve.
  • the tether 150 is not visible under X-rays, such as when the tether 150 is twisted or bent, during ventricular systole, the tether 150 is straightened under the impact of blood flow, so that the heart valve 10 and the mitral valve There is a gap between the fittings, which leads to paravalvular leakage, which affects heart function.
  • the tether 150 by setting the tether 150 to be visible under X-rays, during the follow-up process, by observing the state of the tether 150, it can also be determined whether there will be a paravalvular leak.
  • the tether 150 may be made of polymer doped with developing materials.
  • the developing material is dispersed in a polymer matrix with good biocompatibility to make the tether 150.
  • the polymer matrix can be silica gel, polypropylene (PP), polyurethane (PU), polyethylene (PE), polyether ether ketone (PEEK), polylactic acid (PLA), polyglycolic acid (PGA), polyhydroxy fatty acid ester ( PHA), polydioxanone (PDO), polycaprolactone (PCL) or ultra-high molecular weight polyethylene (UHMWPE).
  • the developing material can be metal materials such as gold, tungsten, iron, platinum, titanium and its alloys, stainless steel, or non-metallic materials such as barium sulfate, bismuth subcarbonate, and iodides (such as iohexol and iopamidol).
  • the mass of the developing material in the tether 150 is not less than 10% of the mass of the tether 150 to improve the developability of the tether 150 under X-rays.
  • the wire diameter of the tether 150 is 0.02 mm to 5.0 mm, so that the tether 150 can be conveyed normally in the conveyor.
  • the tether 150 is made of polyurethane doped with barium sulfate, and its preparation can be divided into two steps.
  • the first step is melt granulation.
  • the drying temperature can be 60 ⁇ 140°C, and the drying time can be 2 ⁇ 8h.
  • the extruder temperature is 120 ⁇ 200 °C (the temperature of the feed section should not be too high, generally controlled at 120-150°C), the die temperature is 160-190°C, the polyurethane is plasticized and homogenized by the extruder, extruded from the die, and cut Knife cutting to complete granulation.
  • the feeding ratio of polyurethane and barium sulfate is 40:60, the temperature of the feeding section is 145°C, the temperature of the melting section is 165°C, the temperature of the homogenization section is 175°C, and the temperature of the die is 170°C.
  • the second step is extrusion molding.
  • the drying temperature can be 60 ⁇ 140°C
  • the drying time can be 2 ⁇ 8h
  • the screw speed is 0-60rpm
  • the traction speed is controlled at 0-200m/min
  • the tether 150 is obtained.
  • the temperature of the feeding section is controlled at 140°C
  • the temperature of the melting section is controlled at 160°C
  • the homogenization section is controlled at 180°C
  • the head temperature is controlled at 170°C
  • the screw speed is 30rpm
  • the traction speed is 10m/ min
  • the wire diameter of the final tether is 0.15mm.
  • the second embodiment of the present application differs from the first embodiment mainly in that the tether 250 includes a developing thread 251 and a non-developing thread 252.
  • the developing thread 251 and the non-developing thread 252 are woven to form a tether 250.
  • the developed yarn 251 and the non-developed yarn 252 are knitted by twisting.
  • the twist direction may be S, Z direction, or the like.
  • the twist should be moderately controlled, and the preferred twist is 1-100 per meter.
  • the developing thread 251 is a nickel-titanium wire with a diameter of 0.1mm;
  • the non-developing thread 252 is a nylon thread with a specification of 80D/20F; one developing thread 251 and three non-developing threads 252 are added along the S direction. Twist, the twist is 50 per meter, the tether 150 is made, and the wire diameter is 0.3mm.
  • the separate knot of the developed thread 251 will form a larger gap.
  • the knots are easy to unravel during the stretching process.
  • the gap formed after 250 knotting is smaller, and the knotting performance is greatly improved.
  • the developing wire 251 can also be made of other metal materials, such as gold, tungsten, iron, platinum, titanium and its alloys, stainless steel, etc., or can also be a polymer material doped with developing materials.
  • the material of the non-developing line 152 can also be silicone, polypropylene (PP), polyurethane (PU), polyethylene (PE), polyether ether ketone (PEEK), polylactic acid (PLA), polyglycolic acid (PGA), poly Hydroxy fatty acid ester (PHA), polydioxanone (PDO), polycaprolactone (PCL) or ultra-high molecular weight polyethylene (UHMWPE).
  • the tether 350 includes a core layer 353 and a braided layer 354 wrapped around the core layer 353.
  • the core layer 353 is doped with
  • the material is made of polymer materials, and the braided layer 354 is knitted by polymer threads.
  • the above-mentioned tether can be seen under X-rays, and it can solve the problem that the metal tether is difficult to knot, and the mechanical properties of the polymer developing tether are reduced after the developer is added, so as to achieve better knotting and mechanical properties.
  • the developing material is dispersed in a polymer matrix with good biocompatibility to form the core layer 353.
  • the polymer matrix can be silica gel, polypropylene (PP), polyurethane (PU), polyethylene (PE), polyether ether ketone (PEEK), polylactic acid (PLA), polyglycolic acid (PGA), polyhydroxy fatty acid ester ( PHA), polydioxanone (PDO), polycaprolactone (PCL) or ultra-high molecular weight polyethylene (UHMWPE).
  • the developing material can be metal materials such as gold, tungsten, iron, platinum, titanium and its alloys, stainless steel, or non-metallic materials such as barium sulfate, bismuth subcarbonate, and iodide (such as iohexol and iopamidol).
  • the mass of the developing material in the core layer 353 is not less than 10% of the mass of the core layer 353 to improve the developability of the tether 350 under X-rays.
  • the polymer thread of the braid 154 can be prepared by injection molding, extrusion, 3D printing, laser cutting, electrostatic spinning, etc.
  • the material can be various materials with good biocompatibility, including but not limited to ultra-high molecular weight polyethylene (UHMWPE).
  • UHMWPE ultra-high molecular weight polyethylene
  • polytetrafluoroethylene PTFE
  • nylon PA
  • PET polyethylene terephthalate
  • PP polypropylene
  • PU polyurethane
  • PE polyethylene
  • PEEK polyether ether ketone
  • PLA polylactic acid
  • PGA polyglycolic acid
  • PHA polyhydroxy fatty acid ester
  • PDO polydioxanone
  • PCL polycaprolactone
  • the core layer 353 is made of polypropylene doped with tungsten powder by 3D printing
  • the braided layer 354 is made of ultra-high molecular weight polyethylene yarns woven by pressing one by one.
  • the specific preparation method as follows. Firstly, the polypropylene and tungsten powder are dried. The drying temperature can be 60 ⁇ 140°C, and the drying time can be 2 ⁇ 8h.
  • the extruder temperature is 150 ⁇ 230°C (the temperature of the feed section should not be too high, generally controlled at 150 ⁇ 200°C), the die temperature is 190 ⁇ 230°C, the polypropylene is plasticized and homogenized by the extruder and extruded from the die. And after cutting with a cutter, granulation is completed.
  • the feeding ratio of polypropylene and tungsten powder is 80:20, the temperature of the feeding section is 190°C, the temperature of the melting section is 200°C, the temperature of the homogenization section is 210°C, and the temperature of the die is 200°C.
  • the printing filling density, printing temperature, printing speed and other process parameters should be properly controlled.
  • control the printing temperature of 170-250°C, the printing filling density of 50-90%, and the printing speed of 50-200mm/s.
  • the printing temperature is controlled to be 200°C, the printing filling density is 70%, and the printing speed is 50 mm/s.
  • the slicing software is used to generate the .stl model and process parameters into a 3D printing path file Gcode, and the 3D printer prints the core layer 353 under the control of the code, with a wire diameter of 0.1mm.
  • the core layer 353 is placed in the center of the yarn strands, and the yarn strands are woven around the core layer.
  • the yarn strands can be any number of double strands.
  • the knitting can be but not limited to compression knitting such as one pressing one, one pressing two, so that the yarn strands intersperse and weave , The braided rope is made.
  • the core layer 353 may also be made of a polymer material that is not doped with a developing material, and the braided layer is knitted by a polymer wire doped with a developing material.

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Prostheses (AREA)

Abstract

L'invention concerne une valvule cardiaque (10), et une attache (150) pour une valvule cardiaque (10). La valvule cardiaque (10) comprend : une endoprothèse de valvule (100), l'endoprothèse de valvule (100) comprenant une endoprothèse de corps principal (110) et une endoprothèse de jupe (120) disposée sur l'endoprothèse de corps principal (110), l'endoprothèse de jupe (120) s'étendant vers l'extérieur dans la direction radiale de l'endoprothèse de corps principal (110) ; un feuillet de valvule (190), le feuillet de valvule (190) étant disposé dans l'endoprothèse de corps principal (110) ; et l'attache (150), l'attache (150) étant reliée à l'endoprothèse de corps principal (110), et l'attache (150) étant visible sous rayons X. Pendant un processus d'implantation, l'état de l'attache (150) est observé sous rayons X. Si l'attache (150) est dans un état tel qu'un état torsadé ou plié sous rayons X, l'attache (150) peut être tendue pour la rendre droite de façon à garantir que la tension de l'attache (150) et de l'endoprothèse de valvule (100) est appropriée et s'assurer que la valvule cardiaque (10) ne s'adapte pas mal à l'impact du flux sanguin, ce qui permet de réduire la probabilité de fuite périvalvulaire.
PCT/CN2020/091289 2019-05-21 2020-05-20 Attache pour valvule cardiaque, et valvule cardiaque WO2020233598A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910425358.1 2019-05-21
CN201910425358.1A CN111973316B (zh) 2019-05-21 2019-05-21 用于心脏瓣膜的系绳及心脏瓣膜

Publications (1)

Publication Number Publication Date
WO2020233598A1 true WO2020233598A1 (fr) 2020-11-26

Family

ID=73436957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/091289 WO2020233598A1 (fr) 2019-05-21 2020-05-20 Attache pour valvule cardiaque, et valvule cardiaque

Country Status (2)

Country Link
CN (1) CN111973316B (fr)
WO (1) WO2020233598A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113693785A (zh) * 2021-08-19 2021-11-26 启晨(上海)医疗器械有限公司 系绳固定装置

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113198045B (zh) * 2021-04-29 2022-03-11 武汉纺织大学 一种贴合型生物瓣膜及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960686A (zh) * 2004-02-27 2007-05-09 华沙整形外科股份有限公司 辐射透不过的、同轴的整形外科绳设计和方法
US20160074160A1 (en) * 2013-05-30 2016-03-17 Tendyne Holdings, Inc. Structural members for prosthetic mitral valves
US20170156861A1 (en) * 2013-10-23 2017-06-08 Lc Therapeutics, Inc. Percutaneous or Minimally Invasive Cardiac Valve Repair System and Methods of Using the Same
CN109549752A (zh) * 2017-09-25 2019-04-02 先健科技(深圳)有限公司 心脏瓣膜
CN109549753A (zh) * 2017-09-25 2019-04-02 先健科技(深圳)有限公司 心脏瓣膜
CN109549754A (zh) * 2017-09-25 2019-04-02 先健科技(深圳)有限公司 心脏瓣膜
CN208770070U (zh) * 2017-11-07 2019-04-23 先健科技(深圳)有限公司 心脏瓣膜锚固装置及心脏瓣膜
CN209154109U (zh) * 2018-06-29 2019-07-26 先健科技(深圳)有限公司 瓣膜支架及心脏瓣膜
CN110934664A (zh) * 2018-09-25 2020-03-31 先健科技(深圳)有限公司 心脏瓣膜

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1769774A1 (fr) * 2005-10-03 2007-04-04 Noureddine Frid Endoprothèse radio-opaque
CN102429750B (zh) * 2011-08-15 2015-05-20 上海微创医疗器械（集团）有限公司 改进显影性能的血管支架及增强血管支架显影性能的方法
US8900295B2 (en) * 2011-09-26 2014-12-02 Edwards Lifesciences Corporation Prosthetic valve with ventricular tethers
WO2015120122A2 (fr) * 2014-02-05 2015-08-13 Robert Vidlund Appareil et procédés pour la mise en place d'une valve mitrale prothétique par l'artère fémorale
JP6865037B2 (ja) * 2014-03-10 2021-04-28 テンダイン ホールディングス，インコーポレイテッド 人工僧帽弁を位置決めするため及び人工僧帽弁のテザーの荷重を監視するためのデバイス及び方法
AU2016215197B2 (en) * 2015-02-05 2020-01-02 Tendyne Holdings Inc. Expandable epicardial pads and devices and methods for their delivery
CN106725677A (zh) * 2017-01-03 2017-05-31 万越 一种x线显影的久置可吸收缝线
WO2018218121A1 (fr) * 2017-05-26 2018-11-29 The Johns Hopkins University Systèmes et méthodes de traitement de valvules cardiaques présentant un dysfonctionnement
CN109549756B (zh) * 2017-09-25 2021-05-07 先健科技(深圳)有限公司 心脏瓣膜

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960686A (zh) * 2004-02-27 2007-05-09 华沙整形外科股份有限公司 辐射透不过的、同轴的整形外科绳设计和方法
US20160074160A1 (en) * 2013-05-30 2016-03-17 Tendyne Holdings, Inc. Structural members for prosthetic mitral valves
US20170156861A1 (en) * 2013-10-23 2017-06-08 Lc Therapeutics, Inc. Percutaneous or Minimally Invasive Cardiac Valve Repair System and Methods of Using the Same
CN109549752A (zh) * 2017-09-25 2019-04-02 先健科技(深圳)有限公司 心脏瓣膜
CN109549753A (zh) * 2017-09-25 2019-04-02 先健科技(深圳)有限公司 心脏瓣膜
CN109549754A (zh) * 2017-09-25 2019-04-02 先健科技(深圳)有限公司 心脏瓣膜
CN208770070U (zh) * 2017-11-07 2019-04-23 先健科技(深圳)有限公司 心脏瓣膜锚固装置及心脏瓣膜
CN209154109U (zh) * 2018-06-29 2019-07-26 先健科技(深圳)有限公司 瓣膜支架及心脏瓣膜
CN110934664A (zh) * 2018-09-25 2020-03-31 先健科技(深圳)有限公司 心脏瓣膜

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113693785A (zh) * 2021-08-19 2021-11-26 启晨(上海)医疗器械有限公司 系绳固定装置

Also Published As

Publication number Publication date
CN111973316B (zh) 2023-10-20
CN111973316A (zh) 2020-11-24

Similar Documents

Publication Publication Date Title
WO2020233598A1 (fr) Attache pour valvule cardiaque, et valvule cardiaque
US7799038B2 (en) Translumenal apparatus, system, and method
CN105324091A (zh) 假体心脏瓣膜
CN113813089B (zh) 支架锚固系统
CN111110398A (zh) 分体式心脏瓣膜支架及其假体
WO2016126511A2 (fr) Valvule cardiaque prothétique ayant un joint d'étanchéité tubulaire
CN212662031U (zh) 人工心脏瓣膜支架、人工心脏瓣膜及人工心脏瓣膜置换系统
US11648108B2 (en) Heart valve prosthesis
CN109806028B (zh) 心脏瓣膜
US20190053887A1 (en) Lumen Woven Support
CN114340516A (zh) 带密封盘的左心房附件植入物
KR20220063301A (ko) 스텐트
WO2021121292A1 (fr) Valvule cardiaque
US10660647B2 (en) Device for positioning and releasing a closure implant for closing the left atrial appendage
US11045178B2 (en) Closure device
CN111616837A (zh) 一种二尖瓣环缩装置
CN110269725B (zh) 可显影的人工腱索
CN107789095B (zh) 瓣膜成形环的制备方法
JP7166270B2 (ja) ステント及びそれを含む医療機器
JP6188514B2 (ja) 蛇腹状管腔構造体
CN212281775U (zh) 一种二尖瓣环缩装置
US20240016639A1 (en) Occluder Devices for Dynamic Gastric Bypass Device
EP3815627B1 (fr) Dispositif d'adaptation d'un dispositif d'occlusion de l'appendice auriculaire gauche après implantation
US20240016640A1 (en) Tethers for Dynamic Gastric Bypass Device
US20240016638A1 (en) Anastomosis Anchors for Dynamic Gastric Bypass Device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20808663

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20808663

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20808663

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 28.04.2022)